Click here - to use the wp menu builder

Lyndra Therapeutics Welcomes Dr. Patricia Hurter as Chief Executive Officer

June 3, 2019

WATERTOWN, Mass.–(BUSINESS WIRE)–#CEO–Lyndra today announced the appointment of Dr. Patricia Hurter as Chief Executive Officer, effective September 3.

http://www.businesswire.com/news/home/20190602005048/en/Lyndra-Therapeutics-Welcomes-Dr.-Patricia-Hurter-Chief/

Lyndra Therapeutics Welcomes Dr. Patricia Hurter as Chief Executive Officer

Recent Articles

Exicure Granted Orphan Drug Designation by the U.S. Food and Drug Administration for Cavrotolimod

AavantiBio Adds Veteran Life Sciences Executive Douglas J. Swirsky as Chief Financial Officer and Treasurer

Xentria Announces Submission of an Investigational New Drug (IND) Application for XTMAB-16 in the Treatment of Sarcoidosis

Quantum Materials Corp Expands Executive Leadership Team To Execute Growth Strategy

Repertoire Immune Medicines Pre-publishes New Research Identifying Potential Mechanisms for Immune Escape of SARS-CoV-2 Variants to Support Novel Approaches for T Cell Based Therapeutic...